Therapeutic advances in neural regeneration for Huntington's disease.
Journal
Neural regeneration research
ISSN: 1673-5374
Titre abrégé: Neural Regen Res
Pays: India
ID NLM: 101316351
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
received:
03
07
2023
accepted:
03
11
2023
medline:
16
1
2024
pubmed:
16
1
2024
entrez:
16
1
2024
Statut:
ppublish
Résumé
Huntington's disease is a neurodegenerative disease caused by the expansion mutation of a cytosine-adenine-guanine triplet in the exon 1 of the HTT gene which is responsible for the production of the huntingtin (Htt) protein. In physiological conditions, Htt is involved in many cellular processes such as cell signaling, transcriptional regulation, energy metabolism regulation, DNA maintenance, axonal trafficking, and antiapoptotic activity. When the genetic alteration is present, the production of a mutant version of Htt (mHtt) occurs, which is characterized by a plethora of pathogenic activities that, finally, lead to cell death. Among all the cells in which mHtt exerts its dangerous activity, the GABAergic Medium Spiny Neurons seem to be the most affected by the mHtt-induced excitotoxicity both in the cortex and in the striatum. However, as the neurodegeneration proceeds ahead the neuronal loss grows also in other brain areas such as the cerebellum, hypothalamus, thalamus, subthalamic nucleus, globus pallidus, and substantia nigra, determining the variety of symptoms that characterize Huntington's disease. From a clinical point of view, Huntington's disease is characterized by a wide spectrum of symptoms spanning from motor impairment to cognitive disorders and dementia. Huntington's disease shows a prevalence of around 3.92 cases every 100,000 worldwide and an incidence of 0.48 new cases every 100,000/year. To date, there is no available cure for Huntington's disease. Several treatments have been developed so far, aiming to reduce the severity of one or more symptoms to slow down the inexorable decline caused by the disease. In this context, the search for reliable strategies to target the different aspects of Huntington's disease become of the utmost interest. In recent years, a variety of studies demonstrated the detrimental role of neuronal loss in Huntington's disease condition highlighting how the replacement of lost cells would be a reasonable strategy to overcome the neurodegeneration. In this view, numerous have been the attempts in several preclinical models of Huntington's disease to evaluate the feasibility of invasive and non-invasive approaches. Thus, the aim of this review is to offer an overview of the most appealing approaches spanning from stem cell-based cell therapy to extracellular vesicles such as exosomes in light of promoting neurogenesis, discussing the results obtained so far, their limits and the future perspectives regarding the neural regeneration in the context of Huntington's disease.
Identifiants
pubmed: 38227527
doi: 10.4103/1673-5374.390969
pii: 01300535-202409000-00030
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1991-1997Informations de copyright
Copyright © 2024 Copyright: © 2024 Neural Regeneration Research.
Références
Abdollah Zadegan S, Coco HM, Reddy KS, Anderson KM, Teixeira AL, Stimming EF (2023) Frequency and pathophysiology of apathy in Huntington disease: a systematic review and meta-analysis. J Neuropsychiatry Clin Neurosci 35:121–132.
An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, Melov S, Ellerby LM (2012) Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11:253–263.
Ananbeh H, Vodicka P, Kupcova Skalnikova H (2021) Emerging roles of exosomes in Huntington's disease. Int J Mol Sci 22:4085.
Andhale R, Shrivastava D (2022) Huntington's disease: a clinical review. Cureus 14:e28484.
Andrzejewska A, Lukomska B, Janowski M (2019) Mesenchymal stem cells: from roots to boost. Stem Cells 37:855–864.
Araldi RP, D'Amelio F, Vigerelli H, de Melo TC, Kerkis I (2020) Stem cell-derived exosomes as therapeutic approach for neurodegenerative disorders: from biology to biotechnology. Cells 9:2663.
Azidus B (2022a) Clinical extension study for safety and efficacy evaluation of cellavita-HD administration in Huntington's patients. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT04219241. Accessed December 20, 2023
Azidus B (2022b) Dose-response evaluation of the cellavita HD product in patients with Huntington's disease. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT03252535. Accessed December 20, 2023
Azidus B (2022c) Safety evaluation of cellavita HD administered intravenously in participants with Huntington's disease. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT02728115. Accessed December 20, 2023
Bachoud-Lévi AC, Rémy P, Nguyen JP, Brugières P, Lefaucheur JP, Bourdet C, Baudic S, Gaura V, Maison P, Haddad B, Boissé MF, Grandmougin T, Jény R, Bartolomeo P, Dalla Barba G, Degos JD, Lisovoski F, Ergis AM, Pailhous E, Cesaro P, et al. (2000) Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356:1975–1979.
Bachoud-Lévi AC, Gaura V, Brugières P, Lefaucheur JP, Boissé MF, Maison P, Baudic S, Ribeiro MJ, Bourdet C, Remy P, Cesaro P, Hantraye P, Peschanski M (2006) Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 5:303–309.
Bachoud-Lévi AC, on behalf the Multicentric Intracerebral Grafting in Huntington's Disease G (2020) Human fetal cell therapy in Huntington's disease: a randomized, multicenter, phase II trial. Mov Disord 35:1323–1335.
Bachoud-Lévi AC, Massart R, Rosser A (2021) Cell therapy in Huntington's disease: taking stock of past studies to move the field forward. Stem Cells 39:144–155.
Benn CL, Luthi-Carter R, Kuhn A, Sadri-Vakili G, Blankson KL, Dalai SC, Goldstein DR, Spires TL, Pritchard J, Olson JM, van Dellen A, Hannan AJ, Cha JHJ (2010) Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease. J Neuropathol Exp Neurol 69:817–827.
Benraiss A, Goldman SA (2011) Cellular therapy and induced neuronal replacement for Huntington's disease. Neurotherapeutics 8:577–590.
Bergonzoni G, Döring J, Biagioli M (2021) D1R- and D2R-medium-sized spiny neurons diversity: insights into striatal vulnerability to Huntington's disease mutation. Front Cell Neurosci 15:628010.
Bond AM, Ming GL, Song H (2022) What is the relationship between hippocampal neurogenesis across different stages of the lifespan? Front Neurosci 16:891713.
Cebrian-Silla A, Nascimento MA, Redmond SA, Mansky B, Wu D, Obernier K, Romero Rodriguez R, Gonzalez-Granero S, García-Verdugo JM, Lim DA, Álvarez-Buylla A (2021) Single-cell analysis of the ventricular-subventricular zone reveals signatures of dorsal and ventral adult neurogenesis. Elife 10:e67436.
Chen YC, Ma NX, Pei ZF, Wu Z, Do-Monte FH, Keefe S, Yellin E, Chen MS, Yin JC, Lee G, Minier-Toribio A, Hu Y, Bai YT, Lee K, Quirk GJ, Chen G (2020) A NeuroD1 AAV-based gene therapy for functional brain repair after ischemic injury through in vivo astrocyte-to-neuron conversion. Mol Ther 28:217–234.
Cho IK, Hunter CE, Ye S, Pongos AL, Chan AWS (2019) Combination of stem cell and gene therapy ameliorates symptoms in Huntington's disease mice. NPJ Regen Med 4:7.
Cho SR, Benraiss A, Chmielnicki E, Samdani A, Economides A, Goldman SA (2007) Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J Clin Invest 117:2889–2902.
Choi BY, Hong DK, Kang BS, Lee SH, Choi S, Kim HJ, Lee SM, Suh SW (2023) Engineered mesenchymal stem cells over-expressing BDNF protect the brain from traumatic brain injury-induced neuronal death, neurological deficits, and cognitive impairments. Pharmaceuticals 16:436.
Clarke LE, Barres BA (2013) Emerging roles of astrocytes in neural circuit development. Nat Rev Neurosci 14:311–321.
Connor B (2018) Concise review: the use of stem cells for understanding and treating Huntington's disease. Stem Cells 36:146–160.
Curtis MA, Penney EB, Pearson AG, van Roon-Mom WMC, Butterworth NJ, Dragunow M, Connor B, Faull RLM (2003) Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc Natl Acad Sci U S A 100:9023–9027.
D'Egidio F, Castelli V, Cimini A, d'Angelo M (2023) Cell rearrangement and oxidant/antioxidant imbalance in Huntington's disease. Antioxidants 12:571.
Dard RF, Dahan L, Rampon C (2019) Targeting hippocampal adult neurogenesis using transcription factors to reduce Alzheimer's disease-associated memory impairments. Hippocampus 29:579–586.
Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, Sandstrom MI, Skeel RL, Lescaudron L, Dunbar GL (2010) Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behav Brain Res 214:193–200.
Didiot MC, Hall LM, Coles AH, Haraszti RA, Godinho BMDC, Chase K, Sapp E, Ly S, Alterman JF, Hassler MR, Echeverria D, Raj L, Morrissey DV, DiFiglia M, Aronin N, Khvorova A (2016) Exosome-mediated delivery of hydrophobically modified siRNA for Huntingtin mRNA silencing. Mol Ther 24:1836–1847.
Doetsch F (2003) The glial identity of neural stem cells. Nat Neurosci 6:1127–1134.
Doetsch F, García-Verdugo JM, Alvarez-Buylla A (1997) Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J Neurosci 17:5046–5061.
Doetsch F, Caillé I, Lim DA, García-Verdugo JM, Alvarez-Buylla A (1999) Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97:703–716.
Drew CJG, Sharouf F, Randell E, Brookes-Howell L, Smallman K, Sewell B, Burrell A, Kirby N, Mills L, Precious S, Pallmann P, Gillespie D, Hood K, Busse M, Gray WP, Rosser A (2021) Protocol for an open label: phase I trial within a cohort of foetal cell transplants in people with Huntington's disease. Brain Commun 3:fcaa230.
Duan W, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B, Zhao M, Cadet JL, Wong J, Ross CA (2008) Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol Dis 30:312–322.
Ernst A, Alkass K, Bernard S, Salehpour M, Perl S, Tisdale J, Possnert G, Druid H, Frisén J (2014) Neurogenesis in the striatum of the adult human brain. Cell 156:1072–1083.
Fields RD, Araque A, Johansen-Berg H, Lim SS, Lynch G, Nave KA, Nedergaard M, Perez R, Sejnowski T, Wake H (2014) Glial biology in learning and cognition. Neuroscientist 20:426–431.
Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, Nauert GM, Sanberg PR, Kordower JH, Saporta S, Isacson O (2000) Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc Natl Acad Sci U S A 97:13877–13882.
Gauthier LR, Charrin BC, Borrell-Pagès M, Dompierre JP, Rangone H, Cordelières FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127–138.
Ghose J, Sinha M, Das E, Jana NR, Bhattacharyya NP (2011) Regulation of miR-146a by RelA/NFkB and p53 in STHdh(Q111)/Hdh(Q111) cells, a cell model of Huntington's disease. PLoS One 6:e23837.
Ghosh R, Tabrizi SJ (2018) Clinical features of Huntington's disease. Adv Exp Med Biol 1049:1–28.
Gil-Mohapel J, Simpson JM, Ghilan M, Christie BR (2011) Neurogenesis in Huntington's disease: Can studying adult neurogenesis lead to the development of new therapeutic strategies? Brain Res 1406:84–105.
Goldman S (2003) Glia as neural progenitor cells. Trends Neurosci 26:590–596.
Goodliffe JW, Song H, Rubakovic A, Chang W, Medalla M, Weaver CM, Luebke JI (2018) Differential changes to D1 and D2 medium spiny neurons in the 12-month-old Q175+/- mouse model of Huntington's disease. PLoS One 13:e0200626.
Grote HE, Bull ND, Howard ML, Van Dellen A, Blakemore C, Bartlett PF, Hannan AJ (2005) Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur J Neurosci 22:2081–2088.
Gurung S, Perocheau D, Touramanidou L, Baruteau J (2021) The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal 19:47.
Herrmann IK, Wood MJA, Fuhrmann G (2021) Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol 16:748–759.
Huo L, Du X, Li X, Liu S, Xu Y (2021) The emerging role of neural cell-derived exosomes in intercellular communication in health and neurodegenerative diseases. Front Neurosci 15:738442.
Jeon I, Lee N, Li JY, Park IH, Park KS, Moon J, Shim SH, Choi C, Chang DJ, Kwon J, Oh SH, Shin DA, Kim HS, Do JT, Lee DR, Kim M, Kang KS, Daley GQ, Brundin P, Song J (2012) Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells 30:2054–2062.
Jin K, LaFevre-Bernt M, Sun Y, Chen S, Gafni J, Crippen D, Logvinova A, Ross CA, Greenberg DA, Ellerby LM (2005) FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A 102:18189–18194.
Jovicic A, Zaldivar Jolissaint JF, Moser R, Silva Santos MdF, Luthi-Carter R (2013) MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms. PLoS One 8:e54222.
Jurkowski MP, Bettio L, K Woo E, Patten A, Yau SY, Gil-Mohapel J (2020) Beyond the hippocampus and the SVZ: adult neurogenesis throughout the brain. Front Cell Neurosci 14:576444.
Kalluri R, LeBleu VS (2020) The biology, function, and biomedical applications of exosomes. Science 367:eaau6977.
Kandasamy M, Couillard-Despres S, Raber KA, Stephan M, Lehner B, Winner B, Kohl Z, Rivera FJ, Nguyen HP, Riess O, Bogdahn U, Winkler J, von Hörsten S, Aigner L (2010) Stem cell quiescence in the hippocampal neurogenic niche is associated with elevated transforming growth factor-β signaling in an animal model of Huntington disease. J Neuropathol Exp Neurol 69:717–728.
Kandasamy M, Aigner L (2018) Reactive neuroblastosis in Huntington's disease: a putative therapeutic target for striatal regeneration in the adult brain. Front Cell Neurosci 12:37.
Keene CD, Sonnen JA, Swanson PD, Kopyov O, Leverenz JB, Bird TD, Montine TJ (2007) Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 68:2093–2098.
Keene CD, Chang RC, Leverenz JB, Kopyov O, Perlman S, Hevner RF, Born DE, Bird TD, Montine TJ (2009) A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol 117:329–338.
Kerkis I, Araldi RP, Wenceslau CV, Mendes TB, Kerkis I, Araldi RP, Wenceslau CV, Mendes TB (2022) Advances in cellular and cell-free therapy medicinal products for Huntington disease treatment. In: From pathophysiology to treatment of Huntington's disease: IntechOpen doi:10.5772/intechopen.102539
Kim GU, Sung SE, Kang KK, Choi JH, Lee S, Sung M, Yang SY, Kim SK, Kim YI, Lim JH, Seo MS, Lee GW (2021) Therapeutic potential of mesenchymal stem cells (MSCs) and MSC-derived extracellular vesicles for the treatment of spinal cord injury. Int J Mol Sci 22:13672.
Kohl Z, Kandasamy M, Winner B, Aigner R, Gross C, Couillard-Despres S, Bogdahn U, Aigner L, Winkler J (2007) Physical activity fails to rescue hippocampal neurogenesis deficits in the R6/2 mouse model of Huntington's disease. Brain Res 1155:24–33.
Kopyov OV, Jacques S, Lieberman A, Duma CM, Eagle KS (1998) Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol 149:97–108.
Lazic SE, Grote HE, Blakemore C, Hannan AJ, van Dellen A, Phillips W, Barker RA (2006) Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur J Neurosci 23:1829–1838.
Lee M, Liu T, Im W, Kim M (2016) Exosomes from adipose-derived stem cells ameliorate phenotype of Huntington's disease in vitro model. Eur J Neurosci 44:2114–2119.
Lee ST, Im W, Ban JJ, Lee M, Jung KH, Lee SK, Chu K, Kim M (2017) Exosome-based delivery of miR-124 in a Huntington's disease model. J Mov Disord 10:45–52.
Li H, Chen G (2016) In vivo reprogramming for CNS repair: regenerating neurons from endogenous glial cells. Neuron 91:728–738.
Li M, Li J, Chen H, Zhu M (2023) VEGF-expressing mesenchymal stem cell therapy for safe and effective treatment of pain in Parkinson's disease. Cell Transplant 32:9636897221149130.
Li SP, Lin ZX, Jiang XY, Yu XY (2018) Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools. Acta Pharmacol Sin 39:542–551.
Lieberwirth C, Pan Y, Liu Y, Zhang Z, Wang Z (2016) Hippocampal adult neurogenesis: its regulation and potential role in spatial learning and memory. Brain Res 1644:127–140.
Lin YT, Chern Y, Shen CKJ, Wen HL, Chang YC, Li H, Cheng TH, Hsieh-Li HM (2011) Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models. PLoS One 6:e22924.
Lois C, García-Verdugo JM, Alvarez-Buylla A (1996) Chain migration of neuronal precursors. Science (New York, NY) 271:978–981.
Low VF, Dragunow M, Tippett LJ, Faull RLM, Curtis MA (2011) No change in progenitor cell proliferation in the hippocampus in Huntington's disease. Neuroscience 199:577–588.
Medina A, Mahjoub Y, Shaver L, Pringsheim T (2022) Prevalence and incidence of Huntington's disease: an updated systematic review and meta-analysis. Mov Disord 37:2327–2335.
Ming GL, Song H (2011) Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 70:687–702.
Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PW, Gao G (2021) Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Invest 131:e143780-143780.
Niu W, Zang T, Smith Derek K, Vue Tou Y, Zou Y, Bachoo R, Johnson Jane E, Zhang CL (2015) SOX2 reprograms resident astrocytes into neural progenitors in the adult brain. Stem Cell Reports 4:780–794.
Ottoboni L, von Wunster B, Martino G (2020) Therapeutic plasticity of neural stem cells. Front Neurol 11:148.
Pang TYC, Stam NC, Nithianantharajah J, Howard ML, Hannan AJ (2006) Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in huntington's disease transgenic mice. Neuroscience 141:569–584.
Pardo R, Molina-Calavita M, Poizat G, Keryer G, Humbert S, Saudou F (2010) pARIS-htt: an optimised expression platform to study huntingtin reveals functional domains required for vesicular trafficking. Mol Brain 3:17.
Park HJ, Han A, Kim JY, Choi J, Bae HS, Cho GB, Shin H, Shin EJ, Lee KI, Kim S, Lee JY, Song J (2022) SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington's disease. NPJ Regen Med 7:8.
Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W (2008) The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol 210:154–163.
Philpott LM, Kopyov OV, Lee AJ, Jacques S, Duma CM, Caine S, Yang M, Eagle KS (1997) Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. Cell Transplant 6:203–212.
Quan L, Uyeda A, Muramatsu R (2022) Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination. Inflamm Regen 42:7.
Ransome MI, Renoir T, Hannan AJ (2012) Hippocampal neurogenesis, cognitive deficits and affective disorder in Huntington's disease. Neural Plasticity 2012:874387.
Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, Burnstein RM, Menon DK, Gillard JH, Pickard J, Dunnett SB, Nest UK (2002) Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry 73:678–685.
Rosser AE, Busse ME, Gray WP, Badin RA, Perrier AL, Wheelock V, Cozzi E, Martin UP, Salado-Manzano C, Mills LJ, Drew C, Goldman SA, Canals JM, Thompson LM (2022) Translating cell therapies for neurodegenerative diseases: Huntington's disease as a model disorder. Brain 145:1584–1597.
Rossignol J, Boyer C, Leveque X, Fink KD, Thinard R, Blanchard F, Dunbar GL, Lescaudron L (2011) Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes. Behav Brain Res 217:369–378.
Rossignol J, Fink K, Davis K, Clerc S, Crane A, Matchynski J, Lowrance S, Bombard M, Dekorver N, Lescaudron L, Dunbar GL (2014) Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington's disease. Stem Cells 32:500–509.
Roux JC, Zala D, Panayotis N, Borges-Correia A, Saudou F, Villard L (2012) Modification of Mecp2 dosage alters axonal transport through the Huntingtin/Hap1 pathway. Neurobiol Dis 45:786–795.
Ruiz-Idiago J, Pomarol-Clotet E, Salvador R (2023) Longitudinal analysis of neuropsychiatric symptoms in a large cohort of early-moderate manifest Huntington's disease patients. Parkinsonism Relat Disord 106:105228.
Sharma P, Mesci P, Carromeu C, McClatchy DR, Schiapparelli L, Yates JR, Muotri AR, Cline HT (2019) Exosomes regulate neurogenesis and circuit assembly. Proc Natl Acad Sci U S A 116:16086–16094.
Simpson JM, Gil-Mohapel J, Pouladi MA, Ghilan M, Xie Y, Hayden MR, Christie BR (2011) Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiol Dis 41:249–260.
Sivandzade F, Cucullo L (2021) Regenerative stem cell therapy for neurodegenerative diseases: an overview. Int J Mol Sci 22:2153.
Smith-Geater C, Hernandez SJ, Lim RG, Adam M, Wu J, Stocksdale JT, Wassie BT, Gold MP, Wang KQ, Miramontes R, Kopan L, Orellana I, Joy S, Kemp PJ, Allen ND, Fraenkel E, Thompson LM (2020) Aberrant development corrected in adult-onset Huntington's disease iPSC-derived neuronal cultures via WNT signaling modulation. Stem Cell Reports 14:406–419.
Snyder BR, Chiu AM, Prockop DJ, Chan AWS (2010) Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease. PLoS One 5:e9347.
Spires TL, Grote HE, Varshney NK, Cordery PM, Dellen AV, Blakemore C, Hannan AJ (2004) Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci 24:2270–2276.
Tai W, Xu XM, Zhang CL (2020) Regeneration through in vivo cell fate reprogramming for neural repair. Front Cell Neurosci 14:107.
Talifu Z, Liu JY, Pan YZ, Ke H, Zhang CJ, Xu X, Gao F, Yu Y, Du LJ, Li JJ (2023) In vivo astrocyte-to-neuron reprogramming for central nervous system regeneration: a narrative review. Neural Regen Res 18:750–755.
Tartaglione AM, Popoli P, Calamandrei G (2017) Regenerative medicine in Huntington's disease: Strengths and weaknesses of preclinical studies. Neurosci Biobehav Rev 77:32–47.
Tian WJ, Jeon SH, Zhu GQ, Kwon EB, Kim GE, Bae WJ, Cho HJ, Ha US, Hong S-H, Lee JY, Kim KS, Kim SW (2021) Effect of high-BDNF microenvironment stem cells therapy on neurogenic bladder model in rats. Transl Androl Urol 10:345–355.
Tuazon JP, Castelli V, Borlongan CV (2019a) Drug-like delivery methods of stem cells as biologics for stroke. Expert Opin Drug Deliv 16:823–833.
Tuazon JP, Castelli V, Lee JY, Desideri GB, Stuppia L, Cimini AM, Borlongan CV (2019b) Neural stem cells. Adv Exp Med Biol 1201:79–91.
Tung CW, Huang PY, Chan SC, Cheng PH, Yang SH (2021) The regulatory roles of microRNAs toward pathogenesis and treatments in Huntington's disease. J Biomed Sci 28:59.
van Dellen A, Blakemore C, Deacon R, York D, Hannan AJ (2000) Delaying the onset of Huntington's in mice. Nature 404:721–722.
Vatsa P, Negi R, Ansari UA, Khanna VK, Pant AB (2022) Insights of extracellular vesicles of mesenchymal stem cells: a prospective cell-free regenerative medicine for neurodegenerative disorders. Mol Neurobiol 59:459–474.
Verdera HC, Kuranda K, Mingozzi F (2020) AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther 28:723–746.
Wan Y, Ding Y (2023) Strategies and mechanisms of neuronal reprogramming. Brain Res Bull 199:110661.
Wheeler VC, Persichetti F, McNeil SM, Mysore JS, Mysore SS, MacDonald ME, Myers RH, Gusella JF, Wexler NS (2007) Factors associated with HD CAG repeat instability in Huntington disease. J Med Genet. 44:695–701.
Wu T, Yu M, Zhang L, Chen X, Pei Z (2018) I02 Systemic injection of exosomal sirna significantly reduced huntingtin expression in transgenic mice of huntington's disease. J Neurol Neurosurg Psychiatry 89:A88–89.
Wu Z, Parry M, Hou XY, Liu MH, Wang H, Cain R, Pei ZF, Chen YC, Guo ZY, Abhijeet S, Chen G (2020) Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington's disease. Nat Commun 11:1105.
Xia X, Wang Y, Zheng JC (2022) Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases. Transl Neurodegener 11:53.
Xiao B, Zhang SC, Tan EK (2022) Combination therapy using GDNF and cell transplant in Parkinson's disease. Mol Neurodegener 17:49.
Yoon Y, Kim HS, Hong CP, Li E, Jeon I, Park HJ, Lee N, Pei Z, Song J (2020) Neural transplants from human induced pluripotent stem cells rescue the pathology and behavioral defects in a rodent model of Huntington's disease. Front Neurosci 14:558204.
Zhang K, Cheng K (2023) Stem cell-derived exosome versus stem cell therapy. Nat Rev Bioeng doi: 10.1038/s44222-023-00064-2
Zhang Y, Liu Y, Liu H, Tang WH (2019) Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci 9:19.